March 8, 2021 10:53 AM EST

Covid-19 roundup: Merck and Ridgeback report early data for an oral antiviral to fight the pandemic; Austria pulls a batch of AstraZeneca’s vaccine after patient death

Nicole DeFeudis

Editor

A couple of months after scrapping its Covid-19 vaccine program, Merck has read out early data for an oral antiviral it’s developing with Ridgeback Biotherapeutics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Merck and Ridgeback report early data for an oral antiviral to fight the pandemic; Austria pulls a batch of AstraZeneca’s vaccine after patient death

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Covid-19 roundup: Mer­ck and Ridge­back re­port ear­ly da­ta for an oral an­tivi­ral to fight the pan­dem­ic; Aus­tria pulls a batch of As­traZeneca’s vac­cine af­ter pa­tient death

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Covid-19 roundup: Merck and Ridgeback report early data for an oral antiviral to fight the pandemic; Austria pulls a batch of AstraZeneca’s vaccine after patient death

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva